The weight-loss drugs that have transformed obesity medicine for millions of Americans carry specific safety risks in adults over 65 that differ significantly from those in younger patients, and those risks are not routinely addressed in the prescribing frameworks developed before older adults were widely eligible for coverage. As Medicare coverage expansions in 2025 and 2026 extend GLP-1 drugs to millions of older Americans for the first time, researchers and clinicians are urging a different approach for this age group: more careful baseline assessment, slower dosing, higher protein targets, and proactive monitoring for muscle loss, malnutrition, and bone density decline.
The concern is grounded in a specific physiological reality: up to 40% of total weight lost on high-efficacy GLP-1 medications is lean body mass, not fat, according to body composition studies cited in recent Harvard Science Review analysis and a Nature Reviews Endocrinology correspondence published in 2026. In younger adults with excess weight, losing some muscle alongside fat is manageable. In an adult over 65 who already has reduced baseline muscle mass, impaired anabolic response to protein, and a higher fracture risk, additional muscle and bone loss is not a minor side effect. It can be the difference between independent living and disability.
